---
document_datetime: 2025-12-02 05:25:30
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/xevudy.html
document_name: xevudy.html
version: success
processing_time: 0.1283242
conversion_datetime: 2025-12-24 03:05:04.836692
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Xevudy

[RSS](/en/individual-human-medicine.xml/67531)

##### Authorised

This medicine is authorised for use in the European Union

sotrovimab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Xevudy](#news-on)
- [Related content](#related-content-72352)
- [More information on Xevudy](#related-medicines)

- Rolling review
- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Xevudy is a medicine used for treating COVID-19 in adults and adolescents (from 12 years of age and weighing at least 40 kilograms) who do not require supplemental oxygen and who are at increased risk of the disease becoming severe.

Xevudy contains the active substance sotrovimab.

Expand section

Collapse section

## How is Xevudy used?

Xevudy is given as a single treatment by infusion (drip) into a vein. The recommended dose is 500 mg given within 5 days of the patient developing symptoms of COVID-19. The medicine can only be obtained with a prescription and should be given in healthcare facilities where patients can be adequately monitored during infusion and for one hour afterwards so that they can be managed in case they develop severe allergic reactions, including anaphylaxis.

For more information about using Xevudy, see the package leaflet or contact your doctor or pharmacist.

## How does Xevudy work?

The active substance of Xevudy, sotrovimab, is a monoclonal antibody, a type of protein that has been designed to recognise and attach to a specific structure (called an antigen). Sotrovimab has been designed to attach to the spike protein of SARS-CoV-2 (the virus that causes COVID-19). When sotrovimab attaches to the spike protein, the virus is unable to enter the body's cells.

## What benefits of Xevudy have been shown in studies?

A main study involving 1,057 patients with COVID-19 and at least one underlying condition putting them at risk of severe COVID-19 showed that Xevudy led to fewer patients requiring hospitalisation or dying within 29 days of treatment when compared with placebo (a dummy treatment). Of the patients at increased risk of their illness becoming severe, 1% of those treated with Xevudy (6 out 528) were hospitalised for longer than 24 hours within 29 days of treatment compared with 6% of patients on placebo (30 out of 529), 2 of whom died.

The majority of patients in the study were infected with the original SARS-CoV-2 virus. Some patients were infected with variants including Alpha and Epsilon. Based on laboratory studies, Xevudy is also expected to be active against other variants (including Omicron).

## What are the risks associated with Xevudy?

The most common side effects (which may affect between 1 and 2 in 100 patients) are hypersensitivity (allergic) reactions and infusion-related reactions.

The most serious side effect (affecting around 5 in 10,000 patients) was anaphylaxis (severe allergic reaction).

For the full list of side effects and restrictions of Xevudy, see the package leaflet.

## Why is Xevudy authorised in the EU?

Xevudy was shown to be effective at reducing the risk of hospitalisation or death in patients with COVID-19 at increased risk of the disease becoming severe. The safety profile of Xevudy is considered favourable. The European Medicines Agency decided that Xevudy's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Xevudy?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Xevudy have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Xevudy are continuously monitored. Suspected side effects reported with Xevudy are carefully evaluated and any necessary action taken to protect patients.

## Other information about Xevudy

Xevudy received a marketing authorisation valid throughout the EU on 17 December 2021.

Xevudy : EPAR - Medicine overview

Reference Number: EMA/720729/2021

English (EN) (128.84 KB - PDF)

**First published:** 17/12/2021

**Last updated:** 21/12/2021

[View](/en/documents/overview/xevudy-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-657)

български (BG) (141.86 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/bg/documents/overview/xevudy-epar-medicine-overview_bg.pdf)

español (ES) (118.99 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/es/documents/overview/xevudy-epar-medicine-overview_es.pdf)

čeština (CS) (109.36 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/cs/documents/overview/xevudy-epar-medicine-overview_cs.pdf)

dansk (DA) (128.13 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/da/documents/overview/xevudy-epar-medicine-overview_da.pdf)

Deutsch (DE) (121.62 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/de/documents/overview/xevudy-epar-medicine-overview_de.pdf)

eesti keel (ET) (108.1 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/et/documents/overview/xevudy-epar-medicine-overview_et.pdf)

ελληνικά (EL) (153.71 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/el/documents/overview/xevudy-epar-medicine-overview_el.pdf)

français (FR) (119.9 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/fr/documents/overview/xevudy-epar-medicine-overview_fr.pdf)

hrvatski (HR) (150.91 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/hr/documents/overview/xevudy-epar-medicine-overview_hr.pdf)

italiano (IT) (118.54 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/it/documents/overview/xevudy-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (149.99 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/lv/documents/overview/xevudy-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (109.36 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/lt/documents/overview/xevudy-epar-medicine-overview_lt.pdf)

magyar (HU) (150.11 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/hu/documents/overview/xevudy-epar-medicine-overview_hu.pdf)

Malti (MT) (135.76 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/mt/documents/overview/xevudy-epar-medicine-overview_mt.pdf)

Nederlands (NL) (128.72 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/nl/documents/overview/xevudy-epar-medicine-overview_nl.pdf)

polski (PL) (144.15 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/pl/documents/overview/xevudy-epar-medicine-overview_pl.pdf)

português (PT) (119.85 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/pt/documents/overview/xevudy-epar-medicine-overview_pt.pdf)

română (RO) (140.08 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/ro/documents/overview/xevudy-epar-medicine-overview_ro.pdf)

slovenčina (SK) (140.03 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/sk/documents/overview/xevudy-epar-medicine-overview_sk.pdf)

slovenščina (SL) (138.51 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/sl/documents/overview/xevudy-epar-medicine-overview_sl.pdf)

Suomi (FI) (126.9 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/fi/documents/overview/xevudy-epar-medicine-overview_fi.pdf)

svenska (SV) (126.8 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/sv/documents/overview/xevudy-epar-medicine-overview_sv.pdf)

Xevudy : EPAR - Risk-management-plan

English (EN) (4.24 MB - PDF)

**First published:** 16/12/2021

**Last updated:** 07/11/2024

[View](/en/documents/rmp/xevudy-epar-risk-management-plan_en.pdf)

## Product information

Xevudy : EPAR - Product information

English (EN) (358.87 KB - PDF)

**First published:** 16/12/2021

**Last updated:** 17/06/2025

[View](/en/documents/product-information/xevudy-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-30)

български (BG) (440.24 KB - PDF)

**First published:**

16/12/2021

**Last updated:**

17/06/2025

[View](/bg/documents/product-information/xevudy-epar-product-information_bg.pdf)

español (ES) (314.4 KB - PDF)

**First published:**

16/12/2021

**Last updated:**

17/06/2025

[View](/es/documents/product-information/xevudy-epar-product-information_es.pdf)

čeština (CS) (390.39 KB - PDF)

**First published:**

16/12/2021

**Last updated:**

17/06/2025

[View](/cs/documents/product-information/xevudy-epar-product-information_cs.pdf)

dansk (DA) (348.36 KB - PDF)

**First published:**

16/12/2021

**Last updated:**

17/06/2025

[View](/da/documents/product-information/xevudy-epar-product-information_da.pdf)

Deutsch (DE) (312.81 KB - PDF)

**First published:**

16/12/2021

**Last updated:**

17/06/2025

[View](/de/documents/product-information/xevudy-epar-product-information_de.pdf)

eesti keel (ET) (323.48 KB - PDF)

**First published:**

16/12/2021

**Last updated:**

17/06/2025

[View](/et/documents/product-information/xevudy-epar-product-information_et.pdf)

ελληνικά (EL) (416.76 KB - PDF)

**First published:**

16/12/2021

**Last updated:**

17/06/2025

[View](/el/documents/product-information/xevudy-epar-product-information_el.pdf)

français (FR) (331.23 KB - PDF)

**First published:**

16/12/2021

**Last updated:**

17/06/2025

[View](/fr/documents/product-information/xevudy-epar-product-information_fr.pdf)

hrvatski (HR) (365.22 KB - PDF)

**First published:**

16/12/2021

**Last updated:**

17/06/2025

[View](/hr/documents/product-information/xevudy-epar-product-information_hr.pdf)

íslenska (IS) (322.13 KB - PDF)

**First published:**

16/12/2021

**Last updated:**

17/06/2025

[View](/is/documents/product-information/xevudy-epar-product-information_is.pdf)

italiano (IT) (374.06 KB - PDF)

**First published:**

16/12/2021

**Last updated:**

17/06/2025

[View](/it/documents/product-information/xevudy-epar-product-information_it.pdf)

latviešu valoda (LV) (405.95 KB - PDF)

**First published:**

16/12/2021

**Last updated:**

17/06/2025

[View](/lv/documents/product-information/xevudy-epar-product-information_lv.pdf)

lietuvių kalba (LT) (372.98 KB - PDF)

**First published:**

16/12/2021

**Last updated:**

17/06/2025

[View](/lt/documents/product-information/xevudy-epar-product-information_lt.pdf)

magyar (HU) (392.79 KB - PDF)

**First published:**

16/12/2021

**Last updated:**

17/06/2025

[View](/hu/documents/product-information/xevudy-epar-product-information_hu.pdf)

Malti (MT) (398.5 KB - PDF)

**First published:**

16/12/2021

**Last updated:**

17/06/2025

[View](/mt/documents/product-information/xevudy-epar-product-information_mt.pdf)

Nederlands (NL) (373.14 KB - PDF)

**First published:**

16/12/2021

**Last updated:**

17/06/2025

[View](/nl/documents/product-information/xevudy-epar-product-information_nl.pdf)

norsk (NO) (318.92 KB - PDF)

**First published:**

16/12/2021

**Last updated:**

17/06/2025

[View](/no/documents/product-information/xevudy-epar-product-information_no.pdf)

polski (PL) (412.03 KB - PDF)

**First published:**

16/12/2021

**Last updated:**

17/06/2025

[View](/pl/documents/product-information/xevudy-epar-product-information_pl.pdf)

português (PT) (308.83 KB - PDF)

**First published:**

16/12/2021

**Last updated:**

17/06/2025

[View](/pt/documents/product-information/xevudy-epar-product-information_pt.pdf)

română (RO) (373.42 KB - PDF)

**First published:**

16/12/2021

**Last updated:**

17/06/2025

[View](/ro/documents/product-information/xevudy-epar-product-information_ro.pdf)

slovenčina (SK) (370.4 KB - PDF)

**First published:**

16/12/2021

**Last updated:**

17/06/2025

[View](/sk/documents/product-information/xevudy-epar-product-information_sk.pdf)

slovenščina (SL) (341.08 KB - PDF)

**First published:**

16/12/2021

**Last updated:**

17/06/2025

[View](/sl/documents/product-information/xevudy-epar-product-information_sl.pdf)

Suomi (FI) (369.28 KB - PDF)

**First published:**

16/12/2021

**Last updated:**

17/06/2025

[View](/fi/documents/product-information/xevudy-epar-product-information_fi.pdf)

svenska (SV) (361.92 KB - PDF)

**First published:**

16/12/2021

**Last updated:**

17/06/2025

[View](/sv/documents/product-information/xevudy-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000269654 16/06/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Xevudy : EPAR - All authorised presentations

English (EN) (59.45 KB - PDF)

**First published:** 17/12/2021

**Last updated:** 21/12/2021

[View](/en/documents/all-authorised-presentations/xevudy-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-630)

български (BG) (573.59 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/bg/documents/all-authorised-presentations/xevudy-epar-all-authorised-presentations_bg.pdf)

español (ES) (773.26 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/es/documents/all-authorised-presentations/xevudy-epar-all-authorised-presentations_es.pdf)

čeština (CS) (572.78 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/cs/documents/all-authorised-presentations/xevudy-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (275.91 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/da/documents/all-authorised-presentations/xevudy-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (274.81 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/de/documents/all-authorised-presentations/xevudy-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (773.23 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/et/documents/all-authorised-presentations/xevudy-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (572.47 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/el/documents/all-authorised-presentations/xevudy-epar-all-authorised-presentations_el.pdf)

français (FR) (417.86 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/fr/documents/all-authorised-presentations/xevudy-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (1.05 MB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/hr/documents/all-authorised-presentations/xevudy-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (773.13 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/is/documents/all-authorised-presentations/xevudy-epar-all-authorised-presentations_is.pdf)

italiano (IT) (773.38 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/it/documents/all-authorised-presentations/xevudy-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (573.51 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/lv/documents/all-authorised-presentations/xevudy-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (1.05 MB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/lt/documents/all-authorised-presentations/xevudy-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (916 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/hu/documents/all-authorised-presentations/xevudy-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (573.61 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/mt/documents/all-authorised-presentations/xevudy-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (275.86 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/nl/documents/all-authorised-presentations/xevudy-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (275.9 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/no/documents/all-authorised-presentations/xevudy-epar-all-authorised-presentations_no.pdf)

polski (PL) (1.05 MB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/pl/documents/all-authorised-presentations/xevudy-epar-all-authorised-presentations_pl.pdf)

português (PT) (874.26 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/pt/documents/all-authorised-presentations/xevudy-epar-all-authorised-presentations_pt.pdf)

română (RO) (1.05 MB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/ro/documents/all-authorised-presentations/xevudy-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (572.32 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/sk/documents/all-authorised-presentations/xevudy-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (418.76 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/sl/documents/all-authorised-presentations/xevudy-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (274.79 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/fi/documents/all-authorised-presentations/xevudy-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (275.96 KB - PDF)

**First published:**

17/12/2021

**Last updated:**

21/12/2021

[View](/sv/documents/all-authorised-presentations/xevudy-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Xevudy Active substance sotrovimab International non-proprietary name (INN) or common name sotrovimab Therapeutic area (MeSH) COVID-19 virus infection Anatomical therapeutic chemical (ATC) code J06BD05

### Pharmacotherapeutic group

Immune sera and immunoglobulins

### Therapeutic indication

Xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe COVID-19.

## Authorisation details

EMA product number EMEA/H/C/005676

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

GlaxoSmithKline Trading Services Limited

12 Riverwalk Citywest Business Campus Dublin 24 D24 YK11 Ireland

Opinion adopted 16/12/2021 Marketing authorisation issued 17/12/2021 Revision 22

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Xevudy : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (122.59 KB - PDF)

**First published:** 17/06/2025

[View](/en/documents/procedural-steps-after/xevudy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Xevudy : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (163.21 KB - PDF)

**First published:** 06/05/2022

**Last updated:** 17/06/2025

[View](/en/documents/procedural-steps-after/xevudy-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Xevudy-H-C-005676-II-0026 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/16919/2024

English (EN) (2.71 MB - PDF)

**First published:** 16/12/2024

**Last updated:** 17/12/2024

[View](/en/documents/variation-report/xevudy-h-c-005676-ii-0026-epar-assessment-report-variation_en.pdf)

Xevudy-H-C-005676-P46-11 : EPAR - Assessment report

Adopted

English (EN) (647.05 KB - PDF)

**First published:** 11/12/2024

[View](/en/documents/variation-report/xevudy-h-c-005676-p46-11-epar-assessment-report_en.pdf)

Xevudy-H-C-005676-P46-10 : EPAR - Assessment report

Adopted

Reference Number: EMA/309000/2024

English (EN) (537.52 KB - PDF)

**First published:** 16/08/2024

[View](/en/documents/variation-report/xevudy-h-c-005676-p46-10-epar-assessment-report_en.pdf)

Xevudy-H-C-005676-P46-007, 008 &amp; 009 : EPAR - Assessment report

Adopted

Reference Number: EMA/108127/2024

English (EN) (376.13 KB - PDF)

**First published:** 13/03/2024

[View](/en/documents/variation-report/xevudy-h-c-005676-p46-007-008-009-epar-assessment-report_en.pdf)

Xevudy-H-C-005676-P46-006 : EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/342654/2023

English (EN) (303.85 KB - PDF)

**First published:** 13/09/2023

[View](/en/documents/variation-report/xevudy-h-c-005676-p46-006-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Xevudy : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/694191/2021

English (EN) (4.7 MB - PDF)

**First published:** 07/01/2022

[View](/en/documents/assessment-report/xevudy-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Xevudy

Adopted

Reference Number: EMA/CHMP/694182/2021

English (EN) (113.33 KB - PDF)

**First published:** 16/12/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-xevudy_en.pdf)

#### News on Xevudy

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-december-2024) 13/12/2024

[ETF warns that monoclonal antibodies may not be effective against emerging strains of SARS-CoV-2](/en/news/etf-warns-monoclonal-antibodies-may-not-be-effective-against-emerging-strains-sars-cov-2) 09/12/2022

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2021) 17/12/2021

[COVID-19: EMA recommends authorisation of antibody medicine Xevudy](/en/news/covid-19-ema-recommends-authorisation-antibody-medicine-xevudy) 16/12/2021

#### Related content

- [Emergency Task Force (ETF) documents: COVID-19](/en/committees/working-parties-other-groups/emergency-task-force-etf/emergency-task-force-etf-recommendations#covid-19-66890)

#### More information on Xevudy

- [EMEA-002899-PIP01-20-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002899-pip01-20-m03)
- [COVID-19 International Drug Pregnancy Registry (COVID-PR) - post-authorisation study](https://catalogues.ema.europa.eu/study/49846)
- [Prospective cohort study to monitor the emergence of SARSCoV-2 spike viral variants in immunocompromised nonhospitalised patients exposed to sotrovimab in Great Britain: LUNAR study (218407) - post-authorisation study](https://catalogues.ema.europa.eu/study/49384)
- [An open-label, non-comparator, multicenter study to describe the pharmacokinetics (PK), pharmacodynamics (PD; viral load) and safety following a single intravenous or intramuscular dose of sotrovimab in pediatric participants with mild to moderate COVID-19 at high risk of disease progression (COMET-PACE) (215226) - post-authorisation study](https://catalogues.ema.europa.eu/study/47007)
- [XEVUDY General Drug Use Investigation (SARS-CoV-2 Infection) - COVID-19 (217893) - post-authorisation study](https://catalogues.ema.europa.eu/study/103975)

**This page was last updated on** 17/06/2025

## Share this page

[Back to top](#main-content)